Following KEYNOTE 671 and AEGEAN studies, CheckMate 77T led to the FDA approval of a third peri-operative chemoimmunotherapy option in NSCLC with tumors ≥ 4 cm and/or node positivity without EGFR or ALK alterations [43]. Here, ALK is linked to non-small cell lung carcinoma.